The answers are out there, we just don't care to do your homework. His cost average is probably in the 18's or 19's. Research his S4's and you will get your answers. As for the options, he bought them (again, look at the S4's).
Like the good dr. said, email Progenics or Salix and get the definitive answer. Why debate it here when you can just ask the company for clarification?
From the Progenics Press Release (Sept 2010) on starting the P3 oral trial.
Phase 3 Study Design for Oral Methylnaltrexone
The phase 3 study is an international, randomized, double-blind, placebo-controlled trial and plans to enroll approximately 700 chronic, non-cancer pain patients experiencing OIC. Patients will be randomized to receive either placebo or one of three doses of oral methylnaltrexone. Following a two-week screening period, study participants will, on a blinded basis, receive oral methylnaltrexone or placebo once daily for four weeks, then continue, on a blinded basis, to receive oral methylnaltrexone or placebo on an as needed basis for eight additional weeks. The primary efficacy endpoint of the study is the proportion of subjects with a rescue-free bowel movement (RFBM) within four hours of receiving oral methylnaltrexone during the four-week blinded period.
This is from the Progenics Press Release (Dec 2011) for the results of the P3 trial.
The study assessed a once-daily oral methylnaltrexone dose of 150, 300 or 450 mg compared to placebo for 84 days. Subjects received oral methylnaltrexone once daily during the first 28 days and on a PRN basis for the remaining 56 days.
Actually, the oral P3 study was a three month study. Someone cheated on there homework :)
I hoping for around 33 to get in. If it breaks 33, it breaks a 2 1/2 year trendline, which I don't think it will do.
This shutdown is sure not going to speed-up the snail that is currently putting the advisory panel together. Are they waiting for the NKTR application, or is the FDA so screwed up it can't even pull together a panel effeciently? It's like the FDA operates on shutdown mode 24/7 already.
If you were listening to the Progenics webcast, nothing like that was said. Do you have a link to this new information?
Not exactly. He speculated that the Nektar data may be used as part of the advisory meeting. The webcast can be found on the Progenics website (If you want the Relistor info, just listen to the first 10 minutes or so).
Still no date for the advisory panel, it may fall into next year. Also Nektar's data may be involved in the discussions.